237 related articles for article (PubMed ID: 26070095)
1. Relationships between plasma pentraxin 3 levels and inflammation markers patients with tunneled permanent catheter in hemodialysis.
Yigit IP; Dogukan A; Taskapan H; Comert M; Ilhan N; Ulu R; Aygen B
J Vasc Access; 2015; 16(5):377-81. PubMed ID: 26070095
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory status in patients with chronic renal failure: the role of PTX3 and pro-inflammatory cytokines.
Malaponte G; Libra M; Bevelacqua Y; Merito P; Fatuzzo P; Rapisarda F; Cristina M; Naselli G; Stivala F; Mazzarino MC; Castellino P
Int J Mol Med; 2007 Oct; 20(4):471-81. PubMed ID: 17786277
[TBL] [Abstract][Full Text] [Related]
3. Can serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?
Yigit IP; Celiker H; Dogukan A; Ilhan N; Gurel A; Ulu R; Aygen B
Ren Fail; 2015 Feb; 37(1):77-82. PubMed ID: 25347233
[TBL] [Abstract][Full Text] [Related]
4. Potential Correlation Between Circulating Fetuin-A and Pentraxin-3 With Biochemical Parameters of Calcification in Hemodialysis Patients.
Hashemi J; Joshaghani HR; Akaberi A; Hesari Z; Ghanbari R; Mohammadzadeh M; Golshan AR
Arch Iran Med; 2017 Dec; 20(12):752-755. PubMed ID: 29664315
[TBL] [Abstract][Full Text] [Related]
5. Changes in inflammatory markers during a hemodialysis session and their relation to vascular access type.
Rozen-Zvi B; Erman A; Korzets A; Levy-Drummer RS; Chagnac A; Khaskiya M; Zingerman B; Ori Y
J Vasc Access; 2012; 13(4):446-51. PubMed ID: 22729528
[TBL] [Abstract][Full Text] [Related]
6. Hemodialysis induces p66(shc) gene expression in nondiabetic humans: correlations with oxidative stress and systemic inflammation.
Zanetti M; Barazzoni R; Gortan Cappellari G; Burekovic I; Bosutti A; Stocca A; Bianco F; Ianche M; Panzetta G; Guarnieri G
J Ren Nutr; 2011 Sep; 21(5):401-9. PubMed ID: 21439852
[TBL] [Abstract][Full Text] [Related]
7. Gastric bypass-induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers.
Barazzoni R; Palmisano S; Gortan Cappellari G; Giuricin M; Moretti E; Vinci P; Semolic A; Guarnieri G; Zanetti M; Manzini Nd
Surg Obes Relat Dis; 2016 Jan; 12(1):23-32. PubMed ID: 26277450
[TBL] [Abstract][Full Text] [Related]
8. Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients.
Dukkipati R; Molnar MZ; Park J; Jing J; Kovesdy CP; Kajani R; Kalantar-Zadeh K
Semin Dial; 2014; 27(4):415-23. PubMed ID: 24118625
[TBL] [Abstract][Full Text] [Related]
9. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients.
Oldani S; Finazzi S; Bottazzi B; Garlanda C; Baldassarre E; Valaperta S; Cuccovillo I; Albini M; Child M; Montanelli A; Graziani G; Badalamenti S
J Nephrol; 2012; 25(1):120-6. PubMed ID: 21725917
[TBL] [Abstract][Full Text] [Related]
10. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients.
Xu Y; Ding X; Zou J; Liu Z; Jiang S; Xu S; Shen B; Chen Y; Shan Y; Cao X
Ren Fail; 2011; 33(10):998-1004. PubMed ID: 22013933
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of the long pentraxin 3 in paracetamol-induced human acute liver injury.
Craig DG; Lee P; Pryde EA; Walker SW; Beckett GJ; Hayes PC; Simpson KJ
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):359-67. PubMed ID: 23169308
[TBL] [Abstract][Full Text] [Related]
12. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients.
Movilli E; Brunori G; Camerini C; Vizzardi V; Gaggia P; Cassamali S; Scolari F; Parrinello G; Cancarini GC
Blood Purif; 2006; 24(4):387-93. PubMed ID: 16755161
[TBL] [Abstract][Full Text] [Related]
13. Plasma Pentraxin 3 Is Closely Associated with Peripheral Arterial Disease in Hemodialysis Patients and Predicts Clinical Outcome: A 6-Year Follow-Up.
Zhou Y; Zhang J; Zhu M; Lu R; Wang Y; Ni Z
Blood Purif; 2015; 39(4):266-73. PubMed ID: 25924996
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Reis F; Teixeira F; Miranda V; Do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
J Vasc Access; 2008; 9(4):248-53. PubMed ID: 19085894
[TBL] [Abstract][Full Text] [Related]
15. Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study.
Sachdeva M; Kovalchuk O; Bitzer M; Mokrzycki MH
J Vasc Access; 2009; 10(3):174-9. PubMed ID: 19670170
[TBL] [Abstract][Full Text] [Related]
16. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation.
Sjöberg B; Qureshi AR; Anderstam B; Alvestrand A; Bárány P
Blood Purif; 2012; 34(3-4):290-7. PubMed ID: 23235124
[TBL] [Abstract][Full Text] [Related]
17. Plasma pentraxin 3 may be a better marker of peripheral artery disease in hemodialysis patients than C-reactive protein.
Zhou Y; Ni Z; Zhang J; Zhang W; Wu Q; Shen G; Wang Y; Qian J
Vasc Med; 2013 Apr; 18(2):85-91. PubMed ID: 23609129
[TBL] [Abstract][Full Text] [Related]
18. Changes in circulating biomarkers during a single hemodialysis session.
Yamamoto T; Nascimento MM; Hayashi SY; Qureshi AR; Waniewski J; Brodin LÅ; Anderstam B; Lind B; Riella MC; Seeberger A; Lindholm B
Hemodial Int; 2013 Jan; 17(1):59-66. PubMed ID: 22716238
[TBL] [Abstract][Full Text] [Related]
19. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.
Buda V; Andor M; Cristescu C; Voicu M; Cochera F; Tuduce P; Petrescu L; Tomescu MC
Ir J Med Sci; 2017 Aug; 186(3):621-629. PubMed ID: 28220370
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis.
Nur E; van Beers EJ; Martina S; Cuccovillo I; Otten HM; Schnog JJ; Meijers JC; Mantovani A; Brandjes DP; Bottazzi B; Biemond BJ;
Blood Cells Mol Dis; 2011 Mar; 46(3):189-94. PubMed ID: 21256776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
